OTC Markets OTCQX - Delayed Quote USD
Interpace Biosciences, Inc. (IDXG)
As of 11:00 AM EST. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
44,893.0000
40,214.0000
31,838.0000
33,117.0000
32,398.0000
Cost of Revenue
17,749.0000
16,310.0000
13,607.0000
14,314.0000
21,673.0000
Gross Profit
27,144.0000
23,904.0000
18,231.0000
18,803.0000
10,725.0000
Operating Expense
20,788.0000
21,093.0000
22,071.0000
24,567.0000
34,702.0000
Operating Income
6,356.0000
2,811.0000
-3,840.0000
-5,764.0000
-23,977.0000
Net Non Operating Interest Income Expense
-782.0000
-1,008.0000
-1,008.0000
-1,040.0000
-549.0000
Other Income Expense
-672.0000
-674.0000
-988.0000
-938.0000
-1,622.0000
Pretax Income
4,902.0000
1,129.0000
-5,836.0000
-7,742.0000
-26,148.0000
Tax Provision
17.0000
17.0000
29.0000
-705.0000
53.0000
Net Income Common Stockholders
4,700.0000
802.0000
-21,958.0000
-14,943.0000
-29,484.0000
Diluted NI Available to Com Stockholders
4,700.0000
802.0000
-21,958.0000
-14,943.0000
-29,484.0000
Basic EPS
1.08
0.19
-5.18
-3.61
-7.32
Diluted EPS
1.07
0.18
-5.18
-3.61
-7.32
Basic Average Shares
4,367.2500
4,317.0000
4,238.0000
4,135.0000
4,029.0000
Diluted Average Shares
4,400.7500
4,364.0000
4,238.0000
4,135.0000
4,029.0000
Total Operating Income as Reported
6,349.0000
2,804.0000
-3,617.0000
-6,336.0000
-26,066.0000
Total Expenses
38,537.0000
37,403.0000
35,678.0000
38,881.0000
56,375.0000
Net Income from Continuing & Discontinued Operation
4,700.0000
802.0000
-21,958.0000
-14,943.0000
-26,451.0000
Normalized Income
4,891.9757
1,118.8950
-6,041.1700
-6,528.8690
-24,676.0300
Interest Expense
782.0000
1,008.0000
1,008.0000
1,040.0000
549.0000
Net Interest Income
-782.0000
-1,008.0000
-1,008.0000
-1,040.0000
-549.0000
EBIT
5,684.0000
2,137.0000
-4,828.0000
-6,702.0000
-25,599.0000
EBITDA
6,407.0000
3,738.0000
-1,326.0000
-1,328.0000
-20,098.0000
Reconciled Cost of Revenue
17,053.0000
15,570.0000
11,375.0000
12,132.0000
20,633.0000
Reconciled Depreciation
723.0000
1,601.0000
3,502.0000
5,374.0000
5,501.0000
Net Income from Continuing Operation Net Minority Interest
4,885.0000
1,112.0000
-5,865.0000
-7,037.0000
-26,201.0000
Total Unusual Items Excluding Goodwill
-7.0000
-7.0000
223.0000
-559.0000
-2,089.0000
Total Unusual Items
-7.0000
-7.0000
223.0000
-559.0000
-2,089.0000
Normalized EBITDA
6,414.0000
3,745.0000
-1,549.0000
-769.0000
-18,009.0000
Tax Rate for Calcs
0.0000
0.0000
0.0002
0.0001
0.0003
Tax Effect of Unusual Items
-0.0243
-0.1050
46.8300
-50.8690
-564.0300
12/31/2020 - 7/9/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PMD Psychemedics Corporation
2.3300
0.00%
PRPO Precipio, Inc.
6.25
+1.62%
IJF.DU Icon PLC
176.25
-1.62%
OL0.DU Devyser Diagnostics AB
11.15
0.00%
IDGXF Integrated Diagnostics Holdings plc
0.3410
-27.75%
EZB.SG Enzo Biochem Inc
0.9700
+0.52%
IBXXF Imagion Biosystems Limited
0.0350
+45.83%
XGN Exagen Inc.
2.8001
-6.04%
BDSX Biodesix, Inc.
1.2750
-5.19%
CNER China New Energy Group Co.
0.0050
+42.86%